Galderma Scores Twin Approvals for Nemolizumab in Europe
The European Commission has approved nemolizumab (Nemluvio, Galderma) for the treatment of both moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union (EU). The first-in-class interleukin (IL)-31 blocker is now approved for subcutaneous use for the treatment of moderate-to-severe AD in patients aged 12 years and older who are candidates for systemic therapy, […]